[1] D. Harman, “The biologic clock: the mitochondria?” Journal of the American Geriatrics Society, vol. 20, no. 4, pp. 145–147, 1972.
[2] A. Trifunovic and N. G. Larsson, “Mitochondrial dysfunction as a cause of ageing,” Journal of Internal Medicine, vol. 263, no. 2, pp. 167–178, 2008.
[3] I. R. Lanza and K. S. Nair, “Mitochondrial function as a determinant of life span,” Pflugers Archiv European Journal of Physiology, vol. 459, no. 2, pp. 277–289, 2010.
[4] L. Guarente, “Mitochondria-A nexus for aging, calorie restriction, and sirtuins?” Cell, vol. 132, no. 2, pp. 171–176, 2008.
[5] C. Handschin, “The biology of PGC-1α and its therapeutic potential,” Trends in Pharmacological Sciences, vol. 30, no. 6, pp. 322–329, 2009.
[6] T. Wenz, “PGC-1α activation as a therapeutic approach in mitochondrial disease,” IUBMB Life, vol. 61, no. 11, pp. 1051–1062, 2009.
[7] M. Saraste, “Oxidative phosphorylation at the fin de siecle,” Science, vol. 283, no. 5407, pp. 1488–1493, 1999.
[8] S. Orrenius, V. Gogvadze, and B. Zhivotovsky, “Mitochondrial oxidative stress: implications for cell death,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 143–183, 2007.
[9] A. Y. Andreyev, YU. E. Kushnareva, and A. A. Starkov, “Mitochondrial metabolism of reactive oxygen species,” Biochemistry, vol. 70, no. 2, pp. 200–214, 2005.
[10] E. Cadenas and K. J. A. Davies, “Mitochondrial free radical generation, oxidative stress, and aging,” Free Radical Biology and Medicine, vol. 29, no. 3-4, pp. 222–230, 2000.
[11] J. St-Pierre, J. A. Buckingham, S. J. Roebuck, and M. D. Brand, “Topology of superoxide production from different sites in the mitochondrial electron transport chain,” The Journal of Biological Chemistry, vol. 277, no. 47, pp. 44784– 44790, 2002.
[12] J. Miquel, A. C. Economos, J. Fleming, and J. E. Johnson, “Mitochondrial role in cell aging,” Experimental Gerontology, vol. 15, no. 6, pp. 575–591, 1980.
[13] C. C. Kujoth, A. Hiona, T. D. Pugh et al., “Medicine: mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging,” Science, vol. 309, no. 5733, pp. 481–484, 2005.
[14] A. Trifunovic, A. Hansson, A. Wredenberg et al., “Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 50, pp. 17993–17998, 2005.
[15] J. Wang, J. P. Silva, C. M. Gustafsson, P. Rustin, and N. G. Larsson, “Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 4038–4043, 2001.
[16] R. S. Balaban, S. Nemoto, and T. Finkel, “Mitochondria, oxidants, and aging,” Cell, vol. 120, no. 4, pp. 483–495, 2005.
[17] H. Van Remmen, Y. Ikeno, M. Hamilton et al., “Life- long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging,” Physiological Genomics, vol. 16, pp. 29–37, 2004.
[18] H. Van Remmen, W. Qi, M. Sabia et al., “Multiple deficiencies in antioxidant enzymes in mice result in a compound increase in sensitivity to oxidative stress,” Free Radical Biology and Medicine, vol. 36, no. 12, pp. 1625–1634, 2004.
[19] T. T. Huang, E. J. Carlson, A. M. Gillespie, Y. Shi, and C. J. Epstein, “Ubiquitous overexpression of CuZn superoxide dismutase does not extend life span in mice,” Journals of Gerontology—Series A, vol. 55, no. 1, pp. B5–B9, 2000.
[20] S. Miwa, K. Riyahi, L. Partridge, and M. D. Brand, “Lack of correlation between mitochondrial reactive oxygen species production and life span in Drosophila,” Annals of the New York Academy of Sciences, vol. 1019, pp. 388–391, 2004.
[21] H.-Y. Lee, C. S. Choi, A. L. Birkenfeld et al., “Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance,” Cell Metabolism, vol. 12, no. 6, pp. 668–674, 2010.
[22] D. F. Dai, L. F. Santana, M. Vermulst et al., “Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging,” Circulation, vol. 119, no. 21, pp. 2789–2797, 2009.
[23] P. M. Treuting, N. J. Linford, S. E. Knoblaugh et al., “Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria,” Journals of Gerontology—Series A, vol. 63, no. 8, pp. 813–824, 2008.
[24] S. E. Schriner, N. J. Linford, G. M. Martin et al., “Medecine: extension of murine life span by overexpression of catalase targeted to mitochondria,” Science, vol. 308, no. 5730, pp. 1909–1911, 2005.
[25] A. V. Ergen and M. A. Goodell, “Mechanisms of hematopoietic stem cell aging,” Experimental Gerontology, vol. 45, no. 4, pp. 286–290, 2010.
[26] S. Someya and T. A. Prolla, “Mitochondrial oxidative damage and apoptosis in age-related hearing loss,” Mechanisms of Ageing and Development, vol. 131, no. 7-8, pp. 480–486, 2010.
[27] K. K. Ohlemiller, S. L. McFadden, DA. L. Ding et al., “Targeted deletion of the cytosolic Cu/Zn-superoxide dismutase gene (Sod1) increases susceptibility to noise-induced hearing loss,” Audiology and Neuro-Otology, vol. 4, no. 5, pp. 237–246, 1999.
[28] S. Someya, J. Xu, K. Kondo et al., “Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 46, pp. 19432– 19437, 2009.
[29] F. Li, N. Y. Calingasan, F. Yu et al., “Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice,” Journal of Neurochemistry, vol. 89, no. 5, pp. 1308– 1312, 2004.
[30] S. Melov, P. A. Adlard, K. Morten et al., “Mitochondrial oxidative stress causes hyperphosphorylation of tau,” PLoS ONE, vol. 2, no. 6, article e536, 2007.
[31] M. Ohashi, M. S. Runge, F. M. Faraci, and D. D. Heis- tad, “MnSOD deficiency increases endothelial dysfunction in ApoE-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2331–2336, 2006.
[32] A. M. Vincent, J. W. Russell, K. A. Sullivan et al., “SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy,” Experimental Neurology, vol. 208, no. 2, pp. 216–227, 2007.
[33] D. S. Albers and M. Flint Beal, “Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease,” Journal of Neural Transmission, Supplement, no. 59, pp. 133– 154, 2000.
[34] M. Ristow and K. Zarse, “How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis),” Experimental Gerontology, vol. 45, no. 6, pp. 410–418, 2010.
[35] M. Ristow, K. Zarse, A. Oberbach et al., “Antioxidants prevent health-promoting effects of physical exercise in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 21, pp. 8665–8670, 2009.
[36] G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, “Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis,” Journal of the American Medical Association, vol. 297, no. 8, pp. 842–857, 2007.
[37] W. Yang and S. Hekimi, “A mitochondrial superoxide signal triggers increased longevity in caenorhabditis elegans,” PLoS Biology, vol. 8, no. 12, 2010.
[38] R. Scherz-Shouval and Z. Elazar, “Regulation of autophagy by ROS: physiology and pathology,” Trends in Biochemical Sciences, vol. 36, no. 1, pp. 30–38, 2011.
[39] J. Papaconstantinou, “Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination,” Molecular and Cellular Endocrinology, vol. 299, no. 1, pp. 89– 100, 2009.
[40] M. Giorgio, E. Migliaccio, F. Orsini et al., “Electron transfer between cytochrome c and p66 generates reactive oxygen species that trigger mitochondrial apoptosis,” Cell, vol. 122, no. 2, pp. 221–233, 2005.
[41] R. C. Scarpulla, “Transcriptional paradigms in mammalian mitochondrial biogenesis and function,” Physiological Reviews, vol. 88, no. 2, pp. 611–638, 2008.
[42] R. C. Scarpulla, “Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator,” Annals of the New York Academy of Sciences, vol. 1147, pp. 321–334, 2008.
[43] P. Puigserver and B. M. Spiegelman, “Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator,” Endocrine Reviews, vol. 24, no. 1, pp. 78–90, 2003.
[44] D. Kang and N. Hamasaki, “Mitochondrial transcription factor A in the maintenance of mitochondrial DNA: overview of its multiple roles,” Annals of the New York Academy of Sciences, vol. 1042, pp. 101–108, 2005.
[45] J. Bastin, F. Aubey, A. Rötig, A. Munnich, and F. Djouadi, “Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients’ cells lacking its compo- nents,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1433–1441, 2008.
[46] T. Wenz, F. Diaz, B. M. Spiegelman, and C. T. Moraes, “Activation of the PPAR/PGC-1α pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype,” Cell Metabolism, vol. 8, no. 3, pp. 249–256, 2008.
[47] T. Wenz et al., “A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations,” Journal of Cellular and Molecular Medicine. In press.